ArticleBMC health services research2023

Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy.

Roberto Cairoli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.